These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 18953376)

  • 1. [The pharmacist, rare diseases and orphan medicines].
    Nagore Induráin C; Lacalle E; Arteche L
    An Sist Sanit Navar; 2008; 31 Suppl 2():127-43. PubMed ID: 18953376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of the evolution in the access to orphan medicines in Spain].
    Mestre-Ferrándiz J; Iniesta M; Trapero-Bertran M; Espín J; Brosa M
    Gac Sanit; 2020; 34(2):141-149. PubMed ID: 31014554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Awareness of orphan therapies offer opportunities for pharmacists.
    Traynor K
    Am J Health Syst Pharm; 2013 Sep; 70(18):1564, 1566. PubMed ID: 23988596
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapeutic profile of orphan medicines.
    de Barros CM; Papoila AL
    Pharmacoepidemiol Drug Saf; 2007 Apr; 16(4):435-40. PubMed ID: 16958155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [European incentives for orphan medicinal products].
    Enzmann H; Lütz J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 May; 51(5):500-8. PubMed ID: 18696141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
    Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
    Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orphan Drugs in Oncology.
    Korchagina D; Jaroslawski S; Jadot G; Toumi M
    Recent Results Cancer Res; 2019; 213():109-142. PubMed ID: 30543010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Orphan diseases and orphan medicines: a Belgian and European study].
    Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
    J Pharm Belg; 2009 Dec; (4):131-7. PubMed ID: 20183989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient Access to Medicines for Rare Diseases in European Countries.
    Detiček A; Locatelli I; Kos M
    Value Health; 2018 May; 21(5):553-560. PubMed ID: 29753352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007.
    Orofino J; Soto J; Casado MA; Oyagüez I
    Appl Health Econ Health Policy; 2010; 8(5):301-15. PubMed ID: 20804223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orphan Medicines for Pediatric Use: A Focus on the European Union.
    Bolislis WR; Corriol-Rohou S; Hill-Venning C; Hoogland H; Joos A; King D; Kitcatt V; Le Visage G; Kühler TC
    Clin Ther; 2019 Dec; 41(12):2630-2642. PubMed ID: 31704041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical trials of orphan medicines.
    Buckley BM
    Lancet; 2008 Jun; 371(9629):2051-5. PubMed ID: 18555919
    [No Abstract]   [Full Text] [Related]  

  • 13. Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives.
    John JE
    Drug Discov Today; 2011 Dec; 16(23-24):999-1000. PubMed ID: 22020052
    [No Abstract]   [Full Text] [Related]  

  • 14. Orphan drug designation in Europe: A booster for the research and development of drugs in rare diseases.
    Micallef J; Blin O
    Therapie; 2020 Apr; 75(2):133-139. PubMed ID: 32156423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of orphan drugs prices in France: a regression analysis.
    Korchagina D; Millier A; Vataire AL; Aballea S; Falissard B; Toumi M
    Orphanet J Rare Dis; 2017 Apr; 12(1):75. PubMed ID: 28427466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trials.
    Pariser AR; Xu K; Milto J; Coté TR
    Discov Med; 2011 Apr; 11(59):367-75. PubMed ID: 21524390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drugs for exceptionally rare diseases: do they deserve special status for funding?
    Hughes DA; Tunnage B; Yeo ST
    QJM; 2005 Nov; 98(11):829-36. PubMed ID: 16203824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What impact does 'conventional' economic evaluation have on patient access to new orphan medicines? A comparative study of their reimbursement in Australia (2005-2012).
    Wonder M; Chin G
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):843-50. PubMed ID: 25938794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The challenges of orphan drugs and orphan diseases: real and imagined.
    Hudson I; Breckenridge A
    Clin Pharmacol Ther; 2012 Aug; 92(2):151-3. PubMed ID: 22814659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hope for patients with rare diseases--"orphan" drugs].
    Kuzelová M; Kubácková K; Palágyi M; Smíd M
    Cas Lek Cesk; 2006; 145(4):296-300. PubMed ID: 16639930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.